Department of Molecular Oncology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, Dubravska Cesta 9, 845 05 Bratislava, Slovakia.
1st Department of Propaedeutic Surgery, National and Kapodistrian University of Athens, Vasilissis Sofias 114, 11527 Athens, Greece.
Crit Rev Oncol Hematol. 2022 Dec;180:103865. doi: 10.1016/j.critrevonc.2022.103865. Epub 2022 Nov 2.
Pancreatic neuroendocrine neoplasms (pNENs) are rare cancers with broad challenges for their management. The main clinical obstacles are the high rate of patients diagnosed at advanced stages, lack of prognostic markers for early detection of disease recurrence in resected patients, significant limitations in identifying those who will benefit from adjuvant therapy, and timely recognition of treatment response. Therefore, the discovery of new prognostic and predictive markers is necessary for patient stratification and clinical management. Liquid biopsy, which has revolutionized the field of clinical oncology, is extremely under-investigated in pNENs. This review highlights its potential and the recent advances in related technologies, as candidates for the delivery of the new tools that can help to refine pNEN diagnosis and to personalize treatment. In addition, the opportunities and limitations of available preclinical research models with regard to biomarker research are discussed in light of pNEN clinical needs.
胰腺神经内分泌肿瘤（pNENs）是一种罕见的癌症，其管理存在广泛的挑战。主要的临床障碍包括：患者在晚期诊断的比例高、缺乏用于早期检测切除患者疾病复发的预后标志物、在确定哪些患者将受益于辅助治疗方面存在显著限制，以及及时识别治疗反应。因此，需要发现新的预后和预测标志物，以便对患者进行分层和临床管理。液体活检彻底改变了临床肿瘤学领域，但在 pNEN 中研究得很少。本综述强调了其潜力以及相关技术的最新进展，这些技术可能成为提供新工具的候选者，有助于完善 pNEN 的诊断并实现治疗个体化。此外，还根据 pNEN 的临床需求，讨论了现有临床前研究模型在生物标志物研究方面的机遇和局限性。
